Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates-Reference-Cited by-同舟云学术

Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates

Published:2021-09-29 Issue:1 Volume:40 Page:31-43
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Edney Laura C.^ORCID,Lomas James^ORCID,Karnon Jonathan^ORCID,Vallejo-Torres Laura,Stadhouders Niek^ORCID,Siverskog Jonathan^ORCID,Paulden Mike^ORCID,Edoka Ijeoma P.^ORCID,Ochalek Jessica^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01087-6.pdf

Reference35 articles.

1. Claxton K, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–503.

2. Martin S, Rice N, Smith PC. Does health care spending improve health outcomes? Evidence from English programme budgeting data. J Health Econ. 2008;27(4):826–42.

3. Martin S, Rice N, Smith PC. Comparing costs and outcomes across programmes of health care. Health Econ. 2012;21(3):316–37.

4. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–61.

5. Edney LC, et al. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2018;36(2):239–52.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating a cost-effectiveness threshold for healthcare decision-making in the Greek NHS;Health Policy and Technology;2024-09

2. Cost effectiveness of adopting a postoperative delirium risk prediction tool with non-pharmacological delirium prevention interventions for surgical patients;2024-08-08

3. Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?;PharmacoEconomics;2024-05-11

4. Marginal cost per QALY estimates: What are they good for?;Health Policy;2024-04

5. Reply to Comment on “A Framework for Fair Pricing of Medicines”;PharmacoEconomics;2024-03-13